Subject: Fwd: GLP-1s and Slowed Gastric Emptying: What It Means for Compound Absorption
From: [email-masked]
To: "[email-masked]" <[email-masked]>
Date: Sat, 25 Apr 2026 21:08:09 -0400

---------- Forwarded message ----------
From: Derek from Research Radar <[email-masked]>
Date: Apr 25, 2026 at 2:01 PM -0400
To: [email-masked]
Subject: GLP-1s and Slowed Gastric Emptying: What It Means for Compound Absorption

> One of the most underappreciated mechanisms of GLP-1 receptor agonists isn’t the appetite suppression or the glucose control — it’s the gut motility piece.
> ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     
> Forwarded this email? Subscribe here for more
> GLP-1s and Slowed Gastric Emptying: What It Means for Compound Absorption
> Derek
> Apr 25
>
> READ IN APP
>
> One of the most underappreciated mechanisms of GLP-1 receptor agonists isn’t the appetite suppression or the glucose control — it’s the gut motility piece. And it’s the piece that generates the most confusion when researchers start asking how other orally administered compounds behave alongside a GLP-1 protocol.
> This is worth walking through carefully, because there’s a lot of misinformation floating around — most of it landing on the wrong side of “things won’t absorb.” That’s not what the literature shows. What the literature shows is more nuanced, and understanding the mechanism makes the picture a lot clearer.
> The Mechanism
> GLP-1 receptor agonists slow gastric emptying through a few overlapping pathways.
> The receptors are densely expressed on vagal afferent neurons in the stomach and small intestine. When activated, they reduce antral contractility — the lower stomach’s grinding action that pushes chyme into the duodenum. They increase pyloric tone, meaning the gate between stomach and small intestine clamps down harder and opens less readily. And they dampen the migrating motor complex, the housekeeping wave that normally sweeps the GI tract during fasted states.
> Net effect: food, fluid, and anything else introduced orally sits in the stomach significantly longer before being released into the small intestine, which is where the majority of absorption happens for most compounds.
> Studies on semaglutide and tirzepatide have shown gastric emptying half-times can extend meaningfully, especially in the first weeks of dosing — before partial tachyphylaxis develops and the effect attenuates somewhat.
> The Absorption Question
> Here’s the part worth being clear about: slowed gastric emptying does not mean orally administered compounds fail to absorb. The small intestine is still doing its job. The compound still gets there. The compound still crosses the enterocytes and enters circulation.
> What changes is the timing and shape of the absorption curve. Specifically:
> Tmax shifts later. The peak plasma concentration arrives further out from the time of administration.
> Cmax can be blunted. A flatter, lower peak rather than a sharp one.
> AUC — total exposure — is usually preserved. The area under the curve, meaning how much compound actually entered systemic circulation, tends to be similar across most studied agents.
> That last point is the one most people miss. Slower does not mean less. For most orally administered compounds, the full dose still reaches circulation; it just arrives on a delayed, smoothed-out timeline.
> Where the Kinetics Actually Matter
> The compounds where this PK shift becomes noteworthy in the published literature are the ones where timing of the peak is part of the mechanism, or where a sharp Cmax is what produces the intended effect:
> Fast-onset agents where the curve shape is the effect — the onset profile changes, and the shifted Tmax can create the impression that something isn’t working when in reality it’s still on its way.
> Short half-life compounds taken on a tight timing window — taking one expecting a familiar onset window can produce unexpected results when the peak arrives later than the historical pattern.
> Compounds with narrow therapeutic windows where any PK shift is meaningful — not because absorption is failing, but because the curve has shifted.
> Oral contraceptive formulations — current tirzepatide labeling specifically flags this. The mechanism isn’t a failure of absorption; it’s the altered PK profile, and manufacturer documentation recommends non-oral backup methods around dose escalation.
> The Practical Takeaway
> The point of this writeup isn’t to alarm anyone about absorption. The point is the opposite — to push back against the casual claim that “GLP-1s mean your other compounds won’t absorb.” That’s not what the pharmacokinetic data shows. What the data shows is that absorption kinetics shift: things come on slower, peaks are softer, and the curve stretches.
> For most orally administered research compounds, this is kinetically interesting but not consequential to total exposure.
> The effect is also strongest during dose escalation and the early weeks of a new GLP-1 protocol. As tolerance to the gastric effects develops, gastric emptying speeds back up somewhat — though it doesn’t fully return to baseline while the compound is on board.
> If a research protocol involves a GLP-1 alongside other orally administered compounds where timing matters, the framework is simple: expect onset to be delayed, expect peaks to be softer, and don’t interpret a delayed onset as a failure of the protocol. The compound is in circulation. It’s just taking a longer path to get there.
> Understanding the mechanism is the difference between confusion and clarity here. The gastric emptying effect is real, the PK shift is real, and the total exposure is — in most cases — preserved.
> This article is for research and educational purposes only. The compounds and protocols discussed are intended for in vitro and laboratory research use. Nothing in this article constitutes medical advice, clinical guidance, or recommendations for human consumption.
> Upgrade to paid
> You're currently a free subscriber to Research Radar. For the full experience, upgrade your subscription.
> Upgrade to paid
>
> Share
>
>
> Like
> Comment
> Restack
>
> © 2026 Derek Pruski
> 548 Market Street PMB 72296, San Francisco, CA 94104
> Unsubscribe